CALIFON, NJ, Sept. 14, 2011 /CNW/ - PediatRx Inc. ("PediatRx") (OTCBB:
PEDX), a hospital specialty company with an initial focus on oncology
supportive care products, has entered into a U.S. co-promotion
agreement with Bi-Coastal Pharmaceutical Corp. for AQUORAL™, an
FDA-cleared, prescription-only treatment for xerostomia (the medical
term for dry mouth due to a lack of saliva). Xerostomia can be a
debilitating medical condition and is estimated to impact between 35
and 40 million Americans. It is especially prevalent in patients
undergoing various treatments for cancer and those with Sjögren's
syndrome. It is also common in the elderly and in patients who are
taking prescription medications.
"AQUORAL is an excellent addition to GRANISOL™ in our product
portfolio. Both products may offer significant benefit to patients who
are suffering from the consequences of their oncology treatments. In
addition, we expect that AQUORAL will help further establish PediatRx
in the oncology supportive care arena," said Dr. Cameron Durrant, the
founder of PediatRx. "With both AQUORAL and GRANISOL focused on a
similar target audience, this allows us to leverage our existing
infrastructure, which was previously solely supporting GRANISOL, and is
congruent with our strategy of adding complementary products."
The AQUORAL co-promotion is scheduled to begin immediately. PediatRx
will provide sales support in the United States and be compensated
based on product sales.
AQUORAL is clinically tested and cleared by the FDA. The product is
safe, well tolerated and exhibits none of the side effects associated
with competitive prescription products.
Selected Safety Information
AQUORAL should not be taken if there is sensitivity or allergy to corn
oil, silicon dioxide, aspartame, or artificial flavorings (citrus).
There are no known side effects when using AQUORAL.
GRANISOL is contraindicated in patients with known hypersensitivity to
the drug or any of its components.
QT prolongation has been reported with granisetron. Therefore, GRANISOL
Oral Solution should be used in caution with patients with pre-existing
arrhythmias or cardiac conduction disorders, as this might lead to
clinical consequences. Patients with cardiac disease, on cardio-toxic
chemotherapy, with concomitant electrolyte abnormalities and/or on
concomitant medications that prolong the QT interval are particularly
Safety and effectiveness in pediatric patients have not been
The most common side effects observed with administration of granisetron
were headache, asthenia, constipation, diarrhea, dyspepsia, and
PediatRx Inc. (www.pediatrx.com) is a hospital specialty pharmaceutical
company which focuses on treatments for patients suffering from serious
conditions requiring hospitalization with an initial focus on oncology
supportive care. PediatRx trades on the OTCBB under the ticker symbol
Bi-Coastal Pharmaceutical Corp. is a privately owned specialty
pharmaceutical company headquartered in Red Bank, New Jersey and
founded in 1982.
This press release contains forward-looking statements. Forward-looking
statements are projections of events, revenues, income, future
economics, research, development, reformulation, product performance or
management's plans and objectives for future operations. In some cases
you can identify forward-looking statements by the use of terminology
such as "may", "should", "anticipates", "believes", "expects",
"intends", "forecasts", "plans", "future", "strategy", or words of
similar meaning. Forward-looking statements in this press release
include the Company's anticipation that AQUORAL and Granisol may both
offer significant benefit to patients who are suffering from the
consequences of their oncology treatments, the expectation that AQUORAL
will help further establish the Company in the oncology supportive care
arena and the expectation that the two products will allow the company
to leverage its existing infrastructure.
While these forward-looking statements and any assumptions upon which
they are based are made in good faith and reflect current judgment
regarding the direction of the business operations of PediatRx, actual
results will almost always vary, sometimes materially, from any
estimates, predictions, projections, assumptions or other future
performance suggested in this press release. These statements are
predictions and involve known and unknown risks, uncertainties and
other factors, including the risk that PediatRx cannot execute its
business plan for lack of capital or other resources, distribution,
partnering or licensing/acquisition opportunities, as well as the risks
described in the periodic disclosure documents filed on EDGAR by
PediatRx, copies of which are also available on the company's website.
Any of these risks could cause PediatRx or its industry's actual
results, levels of activity, performance or achievements to be
materially different from those expressed or implied by the
forward-looking statements in this press release. Except as required
by applicable law, including the securities laws of the United States,
PediatRx does not intend to update any of the forward-looking
statements to conform these statements to actual results.
SOURCE PediatRx Inc.
For further information:
Research & Business Development
+1 908 975 0753